{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:18:22Z","timestamp":1793665102317,"version":"4.5.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104917","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:22:43Z","timestamp":1756768963000},"page":"104917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["From R-CHOP to revolution: How CAR T-Cells, ADCs, and bispecific antibodies are transforming DLBCL treatment"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8848-8612","authenticated-orcid":false,"given":"Mohamad","family":"Farhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Mohanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bechara","family":"El Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Catherine Rita","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104917_bib1","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104917_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104917_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104917_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-158278","article-title":"Subcutaneous epcoritamab + R-Dhax\/C in patients with relapsed or refractory diffuse large B-Cell lymphoma eligible for autologous stem cell transplant: updated phase 1\/2 results","volume":"140","author":"Abrisqueta","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib6","article-title":"Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"11","author":"Abrisqueta","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib7","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104917_bib8","article-title":"Diffuse large B-cell lymphoma","author":"Barraclough","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) t cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104917_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line tisagenlecleucel or standard care in aggressive B-Cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib12","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","author":"Brody","year":"2025","journal-title":"Blood Blood. 2024026830."},{"key":"10.1016\/j.critrevonc.2025.104917_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large b cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.104917_bib14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/17512433.2020.1826303","article-title":"Antibody\u2013drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin","volume":"13","author":"Burke","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large b cell lymphoma relapses after chimeric antigen receptor t cell therapy","author":"Byrne","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2025.104917_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib17","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2023.283459","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104917_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.11.005","article-title":"The AntiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after AntiCD19 CAR-T cell therapy","volume":"22","author":"Caimi","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104917_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","article-title":"Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin lymphoma subtypes project","volume":"2014","author":"Cerhan","year":"2014","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.critrevonc.2025.104917_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: new targets and novel therapies","author":"Cheson","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104917_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib22","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019Etudes des lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib23","first-page":"127","article-title":"Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas","author":"Culjkovic-Kraljacic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104917_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7005","article-title":"A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut\/CD79Bmut diffuse large B-cell lymphoma","volume":"13","author":"Deng","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-164915","article-title":"Total costs of care during chimeric antigen receptor T-Cell therapy in patients with Relapsed\/Refractory b cell Non-Hodgkin lymphoma: a large private insurance Claim-Based analysis","volume":"140","author":"Di","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-Cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib28","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104917_bib29","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279802","article-title":"Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","author":"Duell","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104917_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant b cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2025.104917_bib31","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future","author":"Flowers","year":"2012","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.critrevonc.2025.104917_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: Immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2025.104917_bib33","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104917_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8053","article-title":"Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell lymphomas (R\/R DLBCL): primary analysis of a phase II trial from LYSA","volume":"38","author":"Herbaux","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal residual disease assessment in lymphoma: methods and applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25659","article-title":"Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma","volume":"95","author":"Herrera","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0792-4","article-title":"The emerging role of minimal residual disease testing in diffuse large B-Cell lymphoma","author":"Hu","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104917_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104917_bib39","first-page":"138","article-title":"Glofitamab (Glofit) in combination with polatuzumab vedotin (Pola): phase Ib\/II preliminary data support manageable safety and encouraging efficacy in Relapsed\/Refractory (R\/R) diffuse large B-Cell lymphoma (DLBCL)","author":"Hutchings","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib40","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1634\/theoncologist.2019-0395","article-title":"Axicabtagene ciloleucel, an Anti-CD19 chimeric antigen receptor T-Cell therapy for relapsed or refractory large B-Cell lymphoma: practical implications for the community oncologist","volume":"25","author":"Jacobson","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104917_bib41","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104917_bib43","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2023.11.007","article-title":"CD19 CAR-T cell therapy for relapsed or refractory diffuse large b cell lymphoma: why does it fail?","volume":"60","author":"Kinoshita","year":"2023","journal-title":"Semin Hematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib44","doi-asserted-by":"crossref","DOI":"10.5858\/2009-0759-OA.1","article-title":"Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues","author":"Kodali","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib46","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17251","article-title":"Circulating tumour DNA in B-cell lymphomas: current state and future prospects","author":"Lakhotia","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib48","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02562-3","article-title":"Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large b cell lymphoma patients receiving first-line therapy","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib50","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","volume":"8","author":"Linhares","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib52","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as Second-Line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with Refractory,Aggressive Non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib54","article-title":"Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses","volume":"11","author":"Luo","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009145","article-title":"Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas","volume":"7","author":"Lynch","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7512","article-title":"Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): primary analysis of a phase 1b\/2 trial","volume":"39","author":"Magid Diefenbach","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010016","article-title":"Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions","volume":"7","author":"Major","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib58","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor t cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104917_bib60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178623","article-title":"Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib63","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR t consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib65","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib66","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib67","article-title":"Treatment strategies for relapse after CAR T-cell therapy in b cell lymphoma","author":"Negishi","year":"2023","journal-title":"Front Pedia"},{"key":"10.1016\/j.critrevonc.2025.104917_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020007236","article-title":"Genomic subtypes May predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma","author":"Ollila","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-159594","article-title":"Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged <65 and \u226565 years with Relapsed\/Refractory diffuse large B-Cell lymphoma (R\/R DLBCL) and \u22651 prior therapy: subgroup analysis of a phase Ib\/II study","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib71","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib72","unstructured":"Padala, S.A., Kallam, A., 2022. Diffuse Large B Cell Lymphoma - StatPearls; NCBI Bookshelf. StatPearls."},{"key":"10.1016\/j.critrevonc.2025.104917_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211013987","article-title":"Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications","author":"Papageorgiou","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104917_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib76","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104917_bib77","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3332\/ecancer.2021.1242","article-title":"Outcomes of diffuse large B-cell lymphoma in elderly patients-real-world experience from a middle-income country setting","volume":"15","author":"Sarker","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.critrevonc.2025.104917_bib78","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.12.016","article-title":"Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL): a Post-hoc analysis of the SADAL study","volume":"22","author":"Schuster","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104917_bib80","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib81","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib85","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/ refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib86","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-Cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib87","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104917_bib88","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","author":"Shumilov","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib89","article-title":"Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial","author":"Song","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib90","doi-asserted-by":"crossref","DOI":"10.4103\/jcrt.jcrt_269_24","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory diffuse large B-cell lymphoma: a phase III bridging study in Chinese patients","volume":"20","author":"Song","year":"2024","journal-title":"J. Cancer Res Ther."},{"key":"10.1016\/j.critrevonc.2025.104917_bib91","first-page":"38","article-title":"Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel)","author":"Strati","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 t cell-dependent bispecific antibody for the treatment of b cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104917_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell-Engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib95","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib96","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with Relapsed\/Refractory large b cell lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib97","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104917_bib98","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13784","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma in the real world","volume":"109","author":"Vodicka","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib99","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-021-04711-9","article-title":"Polatuzumab vedotin\u2013based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience","volume":"101","author":"Wang","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib100","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-021-01155-2","article-title":"Molecular subgroups of diffuse large b cell lymphoma: biology and implications for clinical practice","author":"Weber","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104917_bib101","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024014907","article-title":"Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase II study","author":"Westin","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104917_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3884","article-title":"Targeting b cell receptor signaling with ibrutinib in diffuse large b cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104917_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large b cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104917_bib104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminhematol.2015.01.006","article-title":"The histological classification of diffuse large B-cell lymphomas","volume":"52","author":"Xie","year":"2015","journal-title":"Semin Hematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib105","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.104917_bib106","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:47:50Z","timestamp":1792986470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":106,"alternative-id":["S1040842825003051"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104917","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From R-CHOP to revolution: How CAR T-Cells, ADCs, and bispecific antibodies are transforming DLBCL treatment","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104917"}}